Jefferies took its Medifast [MED] rating to the equivalent of Buy from Hold, and the price target to $265.0 from $205, in a research note dated 2021-01-25. That figure represents around a 19.91% premium from where the company’s shares closed on Friday. Some new analysts also started their coverage, with B. Riley FBR’s analysts assigning the shares to “a Buy” rating in a research note to investors issued in late June. Meanwhile, Jefferies had lowered its rating on MED to “Hold” from the earlier “Buy”, in a research note produced for clients on February 27, 2020. In addition, there was a downgrade from Dougherty & Company on November 08, 2019. The rater changed MED from “a Buy” to “a Neutral”.
Is Medifast Inc. [NYSE: MED] a Good Buy Right Now?
It should be noted that MED technical indicators for short, intermediate as well as long term progress have placed an overall average of 100% as Buy. The average signal changed from 100% Buy in the last week and compares with 88% Buy in the past month. Data from Medifast Inc.’s Trend Spotter indicated that the signals were Weakest. The stock current average is 0.13 million shares in the past 20 days and the short term average signal indicates a 100% Buy. In the last 50 days, the average trading volume was 0.13 million shares while the medium-term average advocated for 100% Buy. The average long-term signal stands at 100% Buy and the 100-day average volume stands at 0.16 million shares.
MED Price Performance
On Wall Street, Medifast Inc. [NYSE:MED] finished Friday’s session down -0.20% at $220.87. The stock went up to $221.48 at the same session while its lowest single-day price was $217.5462. In the last five days, it saw a rise of about 2.35%, Medifast Inc. shares gained by almost 12.49% since the beginning of the year. However, the share price has dropped to as low as -3.55% below its one year high. On 01/20/21, the company shares recorded $229.00, the highest single-day price it has got to in the last 52-weeks, and a 52-week low was seen on 01/04/21, the same year at $190.69. The company’s shares have inclined by 102.69% in the past year. The 50-day SMA achieved is $197.38 while the 200-day SMA is $151.53. Volume gained to 87245.0 from 81900.0 in the previous session.